1y return+121.0%S&P 500 +20.9%
3y return+73.6%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since September 30, 2021: $105 against $174 in the S&P 500.2
Johnson & JohnsonS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| PTGXProtagonist Therapeutics Inc | $300.2M | 37.6% | |
| NBTXNanobiotix | $212.0M | 26.5% | |
| Meiragtx Hldgs PLCCUSIP G59665102 | $89.7M | 11.2% | |
| RAPPRapport Therapeutics Inc | $74.4M | 9.3% | |
| CTNMContineum Therapeutics Inc | $32.4M | 4.1% | |
| LEGNLegend Biotech Corp | $23.5M | 2.9% | |
| CVRXCvrx Inc | $20.7M | 2.6% | |
| XNCRXencor Inc | $12.0M | 1.5% | |
| CBRSCerebras Systems Inc | $11.8M | 1.5% | New |
| FATEFate Therapeutics Inc | $9.1M | 1.1% | |
| PRCTProcept Biorobotics Corp | $8.1M | 1.0% | |
| NMRANeumora Therapeutics Inc. | $3.1M | 0.4% | |
| VORVor Biopharma Inc | $989K | 0.1% | |
| LABStandard Biotools Inc | $257K | 0.0% | |
| ACETAdicet Bio Inc | $197K | 0.0% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| PTGXProtagonist Therapeutics Inc | September 30, 2021 | +591.8% | $300.2M |
| RAPPRapport Therapeutics Inc | June 30, 2024 | +79.1% | $74.4M |
| VORVor Biopharma Inc | December 31, 2025 | +40.7% | $989K |
| ACETAdicet Bio Inc | December 31, 2025 | +2.6% | $197K |
| Meiragtx Hldgs PLCCUSIP G59665102 | September 30, 2021 | +2.5% | $89.7M |
| CTNMContineum Therapeutics Inc | June 30, 2024 | −6.9% | $32.4M |
| PRCTProcept Biorobotics Corp | September 30, 2021 | −40.8% | $8.1M |
| LEGNLegend Biotech Corp | September 30, 2021 | −42.9% | $23.5M |
| XNCRXencor Inc | December 31, 2021 | −59.9% | $12.0M |
| CVRXCvrx Inc | September 30, 2021 | −68.9% | $20.7M |
Sold off last quarter
- RLYBRallybio Corporation was $1.4M
- Nano-X Imaging Ltd.CUSIP M70700105 was $190K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +21.0% | +14.8% |
| March 31, 2026 | +18.0% | −4.6% |
| December 31, 2025 | +14.0% | +2.4% |
| September 30, 2025 | +35.7% | +7.8% |
| June 30, 2025 | −2.0% | +10.5% |
| March 31, 2025 | −7.2% | −4.6% |
| December 31, 2024 | −9.7% | +2.1% |
| September 30, 2024 | +7.2% | +5.4% |
| June 30, 2024 | −15.3% | +4.0% |
| March 31, 2024 | +0.4% | +10.0% |
| December 31, 2023 | +35.2% | +11.2% |
| September 30, 2023 | −22.3% | −3.6% |
| June 30, 2023 | +26.7% | +8.3% |
| March 31, 2023 | −10.9% | +7.0% |
| December 31, 2022 | +0.2% | +7.1% |
| September 30, 2022 | −2.8% | −5.3% |
| June 30, 2022 | −23.6% | −16.5% |
| March 31, 2022 | −29.2% | −4.9% |
| December 31, 2021 | +1.3% | +10.7% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Johnson & Johnson Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=200406&type=13F-HR&dateb=&owner=include&count=40CIK 200406
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/200406/000090445426000435/Filed August 6, 2026 · accession 0000904454-26-000435